Effects of varying doses of spironolactone without and with nitrates on portal vein pressure and kidney function in partial portal vein ligated rats

Hepatology

Volumn 24, Issue 6, 1996, Pages 1492-1496

  Van De Casteele, Marc ^a   Van Roey, Guy ^a   Nevens, Frederik ^a   Fevery, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ISOSORBIDE 5 NITRATE; NITRATE; SPIRONOLACTONE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FREE WATER CLEARANCE; MALE; NATRIURESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA VOLUME; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; VEIN LIGATION;

EID: 0029908492     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.1996.v24.pm0008938186     Document Type: Article

References (27)

1. Groszmann RJ, Bosch J, Grace ND, Conn HO, Garcia-Tsao G, Navasa M, Alberts J, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401-1407.
2. Komeichi H, Moreau R, Cailmail S, Gaudin C, Lebrec D. Haemodynamic responses to selective blockade of beta 2- and beta 1-adrenoceptors in conscious rats with cirrhosis. J Hepatol 1994;21:779-786.
3. Bosch J, Mastai R, Kravetz D, Bruix J, Gaya J, Rigau J, Rodes J. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. HEPATOLOGY 1984;4:1200-1205.
4. Nevens F, Sprengers D, Feu F, Bosch J, Fevery J. Measurement of variceal pressure with an endoscopic pressure sensitive gauge: validation and effect of propranolol therapy in chronic conditions. J Hepatol 1996;24:66-73.
5. Okumara H, Aramaki T, Katsuta Y, Satomura K, Akaike M, Sekiyama T, Terada H, et al. Reduction in HVPG as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991;86:46-52.
6. Garcia-Pagan JC, Salmeron JM, Feu F, Luca A, Gines P, Piczueta P, Claria J, et al. Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. HEPATOLOGY 1994;19:1095-1099.
7. Nevens F, Lijnen P, Vanbilloen H, Fevery J. The effect of long-term treatment with spironolactone on variceal pressure in patients with portal hypertension without ascites. HEPATOLOGY 1996;23:1047-1052.
8. Navasa M, Chesta J, Bosch J, Rodes J. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology 1989; 96:1110-1118.
9. Garcia-Pagan JC, Feu F, Navasa M, Bru C, Ruiz del Arbol L, Bosch J, Rodes J. Long-term haemodynamic effects of isosorbide-5-mononitrate in patients with cirrhosis and portal hypertension. J Hepatol 1990;11:189-195.
10. Salmeron JM, Ruiz del Arbor L, Gines A, Garcia-Pagan JC, Gines P, Feu F, Claria J, et al. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. HEPATOLOGY 1993;17:800-806.
11. Henriksen JH, Ring-Larsen H. Renal effects of drugs used in the treatment of portal hypertension. HEPATOLOGY 1993;18:688-695.
12. Vorobioff J, Picabea E, Gamen E, Villavicencio R, Bordato J, Bessone F, Tanno H, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal hypertensive patients: long-term hemodynamic and renal effects. HEPATOLOGY 1993;18:477-484.
13. Nevens F, Piczueta MP, Fernandez M, Bosch J, Rodes J. Effects of ritanserine, a selective and specific S2-serotonergic antagonist, on portal pressure and splanchnic hemodynamics in portal hypertensive rats. HEPATOLOGY 1991;14:1174-1178.
14. Brady HR, Brenner BM, Lieberthal W. Acute Renal Failure. In: Brenner BM, ed. The Kidney. Vol 2, Ed 5. Philadelphia: Saunders, 1996:1200-1252.
15. Greenleaf JE, Convertino VA, Mangseth GR. Plasma volume during stress in man: osmolality and red cell volume. J Appl Physiol: Respirat Environ Exercise Physiol 1979;47:1031-1038.
16. Oka M, Manku MS. Spironolactone inhibits vascular reactivity by a prostaglandin related mechanism unconnected with aldosterone. Prostaglandins Med 1981;7:305-319.
17. Dacquet C, Loirand G, Mironneau C, Mironneau J, Pacaud P. Spironolactone inhibition of contraction and calcium channels in rat portal vein. Br J Pharmac 1987;92:535-544.
18. Mironneau J. Calcium channel antagonist effects of spironolactone, an aldosterone antagonist. Am J Cardiol 1990;65:7K-8K.
19. Baron A, Pacaud P, Loirand G, Mironneau C, Mironneau J. Pharmacological block of calcium-activated Cl-current in rat vascular smooth muscle cells in short-term primary culture. Pflügers Arch 1991;419:553-558.
20. Sadée W, Dagcioglu M, Schröder R. Pharmacokinetics of Aldactone® in humans. In: Brendel W, Coraboeuf E, Ebling F, Friis T, Greenwood G, Henderson I, Hökfelt B, et al, eds. Proceedings of symposium 'extrarenal activity of aldosterone and its antagonists.' Amsterdam: Excerpta Medica, 1971:40-44.
21. Ochs HR, Greenblatt DJ, Bodem G, Smith TW. Spironolactone. Review. Am Heart J 1978;96:389-400.
22. Clement DL. Effect of spironolactone on systemic blood pressure, limb blood flow and response to sympathetic stimulation in hypertensive patients. Eur J Clin Pharmacol 1982;21:263-267.
23. Reichen J, Hirlinger A, Ha HR, Sägesser S. Chronic verapamil administration lowers pressure and improves hepatic function in rats with liver cirrhosis. J Hepatol 1986;3:49-58.
24. Navasa M, Bosch J, Reichen J, Bru C, Mastai R, Zysset T, Silva G, et al. Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension. HEPATOLOGY 1988;8:850-854.
25. de Gasparo M, Whitebread SE, Preiswerk G, Jeunemaitre X, Corvol P, Menard J. Antialdosterones: incidence and prevention of sexual side-effects. J Steroid Biochem 1989;32:223-227.
26. Hayes PC, Westaby D, Williams R. Effect and mechanism of action of isosorbide-5-mononitrate. Gut 1988;29:752-755.
27. Bosch J, Garcia-Pagan JC, Feu F, Luca A, Fernàndez M, Piczueta P, Rodés J. New approaches in the pharmacological treatment of portal hypertension. J Hepatol 1993;17(suppl 2):S41-S45.